- Home
- MCVT vs APRE Comparison
MCVT vs APRE Comparison
Compare MCVT & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCVT
- APRE
- Stock Information
- Founded
- MCVT 2007
- APRE 2006
- Country
- MCVT United States
- APRE United States
- Employees
- MCVT N/A
- APRE N/A
- Industry
- MCVT Finance Companies
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MCVT Finance
- APRE Health Care
- Exchange
- MCVT Nasdaq
- APRE Nasdaq
- Market Cap
- MCVT 9.3M
- APRE 10.0M
- IPO Year
- MCVT N/A
- APRE 2019
- Fundamental
- Price
- MCVT $1.84
- APRE $1.71
- Analyst Decision
- MCVT
- APRE Strong Buy
- Analyst Count
- MCVT 0
- APRE 2
- Target Price
- MCVT N/A
- APRE $15.50
- AVG Volume (30 Days)
- MCVT 16.2K
- APRE 50.9K
- Earning Date
- MCVT 08-13-2025
- APRE 08-11-2025
- Dividend Yield
- MCVT N/A
- APRE N/A
- EPS Growth
- MCVT N/A
- APRE N/A
- EPS
- MCVT 0.19
- APRE N/A
- Revenue
- MCVT $3,246,479.00
- APRE $1,284,475.00
- Revenue This Year
- MCVT N/A
- APRE N/A
- Revenue Next Year
- MCVT N/A
- APRE N/A
- P/E Ratio
- MCVT $9.81
- APRE N/A
- Revenue Growth
- MCVT N/A
- APRE 33.27
- 52 Week Low
- MCVT $1.13
- APRE $1.41
- 52 Week High
- MCVT $3.88
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- MCVT 50.24
- APRE 52.34
- Support Level
- MCVT $1.77
- APRE $1.48
- Resistance Level
- MCVT $1.91
- APRE $1.91
- Average True Range (ATR)
- MCVT 0.08
- APRE 0.16
- MACD
- MCVT -0.01
- APRE -0.00
- Stochastic Oscillator
- MCVT 36.11
- APRE 63.14
About MCVT Mill City Ventures III Ltd.
Mill City Ventures III Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that the group provides are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.